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Abstract
Background: Low back pain is a common health complaint resulting in substantial economic burden. Each year,
upwards of 20 randomised controlled trials (RCTs) evaluating interventions for non-specific low back pain are
published. Use of the term non-specific low back pain has been criticised on the grounds of encouraging
heterogeneity and hampering interpretation of findings due to possible heterogeneous causes, challenging meta-
analyses. We explored selection criteria used in trials of treatments for nsLBP.
Methods: A systematic review of English-language reports of RCTs in nsLBP population samples, published
between 2006 and 2012, identified from MEDLINE, EMBASE, and the Cochrane Library databases, using a mixed-
methods approach to analysis. Study inclusion and exclusion criteria were extracted, thematically categorised, and
then descriptive statistics were used to summarise the prevalence by emerging category.
Results: We included 168 studies. Two inclusion themes (anatomical area, and symptoms and signs) were
identified. Anatomical area was most reported as between costal margins and gluteal folds (n = 8, 5%), while low
back pain (n = 150, 89%) with or without referred leg pain (n = 27, 16%) was the most reported symptom. Exclusion
criteria comprised 21 themes. Previous or scheduled surgery (n = 84, 50%), pregnancy (n = 81, 48%), malignancy
(n = 78, 46%), trauma (n = 63, 37%) and psychological conditions (n = 58, 34%) were the most common. Sub-themes
of exclusion criteria mostly related to neurological signs and symptoms: nerve root compromise (n = 44, 26%),
neurological signs (n = 34, 20%) or disc herniation (n = 30, 18%). Specific conditions that were most often exclusion
criteria were spondylolisthesis (n = 35, 21%), spinal stenosis (n = 31, 18%) or osteoporosis (n = 27, 16%).
Conclusion: RCTs of interventions for non-specific low back pain have incorporated diverse inclusion and exclusion
criteria. Guidance on standardisation of inclusion and exclusion criteria for nsLBP trials will increase clinical
homogeneity, facilitating greater interpretation of between-trial comparisons and meta-analyses. We propose a
template for reporting inclusion and exclusion criteria.
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Background
Low back pain (LBP) is a common and costly problem
resulting in a substantial personal, social and economic
burden globally [1, 2]. Low back and neck pain are
ranked fourth in terms of disability-adjusted life years,
and the leading cause of activity limitation and work ab-
sence globally [2–4]. The lifetime prevalence of LBP is
between 60 and 84% [5, 6]. Most episodes of LBP are
self-limiting and not related to serious disease [5, 7]. A
specific cause of LBP is currently identifiable in only a
small minority of people (5–15%) and includes serious
pathology such as malignancy, vertebral fracture, infec-
tion or axial spondyloarthritis [7–9]. The term ‘non-spe-
cific’ LBP (nsLBP) is used to refer to instances where no
specific cause has been identified [7, 8, 10–13]. The term
has no agreed definition despite being used by organisa-
tions such as the World Health Organization, Inter-
national Association for the Study of Pain, Backpain
Europe, and the (UK) National Institute for Health and
Care Excellence [7, 9, 14–22].
The annual rate of publication for randomised con-
trolled trials (RCTs) that test interventions for people
with nsLBP has increased from an average of 5.3 RCTs
per year between 1980 and 1999, to 23.3 per year be-
tween 2000 and 2012 [23]. Interpretation of the results
of these numerous RCTs, requires a good understanding
of the study populations that have been included. Simi-
larly, to synthesise the results of RCTs in meta-analyses
requires study populations to be reasonably homoge-
neous across trials. Study populations are determined by
the selection or eligibility (inclusion and exclusion) cri-
teria that form the framework for sampling [24]. Little
research has examined inclusion and exclusion criteria
used in RCTs of LBP populations [24–26]; studies that
did, found ambiguous identification of neurological in-
volvement in the selection criteria, and inconsistencies
across clinical decision guidelines for LBP. The extent to
which trialists have used a consistent approach to identi-
fying people with nsLBP is currently unclear.
As part of a larger study systematically reviewing RCTs
of treatment for non-specific LBP, the aims relevant to
this paper were to systematically describe the inclusion
and exclusion criteria reported in RCTs that test inter-
ventions for nsLBP, the frequency of reporting criteria
and to classify criteria by theme [23].
Methods
Research methods in low back pain research have devel-
oped over recent decades. To assess current practice in
trials, we searched for all trials of nsLBP in MEDLINE,
EMBASE, and the Cochrane Register of Controlled
Trials, published between January 1, 2006 and January 1,
2012. An example search strategy is included as an
additional file [see Additional file 1].
Two of three reviewers (PB, DR or TB), working in-
dependently, identified all candidate RCT reports by
combining all database hits in an Endnote (Version
14; Thomson Reuters, Philadelphia) library, removing
duplicates, and short-listing by title and abstract. Full-
texts were obtained if the titles and abstract alone
contained insufficient information for assessment
against the criteria (Table 1). Reports that self-
identified as pilot/feasibility studies were excluded as
these are by definition not set up to explore effective-
ness. Additionally, the inclusion criteria might be dif-
ferent because the aims may be different [27].
Further, the inherent problem with low power due to
the small sample sizes used, may not be able to be
overcome using meta-analytical techniques due to the
assumptions about underlying distributions being
unrealistic [28].
Data extraction and analysis
Two of three reviewers (PB, DR or TB) independently
extracted data on inclusion and exclusion criteria re-
ported in the methods section of each included trial.
One reviewer (PA) entered these data into a database.
Following extraction of inclusion and exclusion criteria,
we used expert validation of extracted data on 20% ran-
dom sample of included trials (95,1% level of agreement),
as has been done in other reviews [29, 30].
To identify the categories of reported inclusion and
exclusion criteria, we developed a coding framework
with themes and subthemes. PA, RF and DR first
Table 1 Inclusion and exclusion criteria and the order of their
evaluation
Inclusion criterion
RCTs of nsLBP not failing one of the eight exclusion criteria
Order Exclusion criteria
1 Non-English language reports
2 Studies that were not RCTs or presented insufficient information
for us to determine whether randomisation was used to allocate
participants
3 Reports that self-identified as pilot/feasibility studies
4 Cross-over designs (because of limited utility in the LBP field)
5 RCTs with mixed samples (e.g. neck or thoracic pain in addition
to LBP), samples of participants with radiating leg pain, or
referred pain extending past the knee in reports where LBP was
not described as non-specific, or samples including LBP specific
pathology (e.g. cancer, ankylosing spondylitis, or disc herniation)
or pregnancy
6 Trials using solely objective or psychological outcome measures
7 Non-inferiority designs
8 Follow-up studies with no new outcome measures, and multiple
publications. In the case of multiple publications, we included
the first published article and excluded subsequent publications
RCT = Randomised controlled trial; nsLBP=Non-specific low back pain
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familiarised themselves with the extracted data and
coded each inclusion and exclusion criterion with la-
bels that described their focus, and then grouped
these coded data into clusters of similar interrelated
ideas or concepts to form general categories. We used
a Microsoft Excel (Microsoft, Washington) spread-
sheet to generate a matrix, and the categories were
then ‘charted’ into our framework matrix. We
retained the terminology used within RCT reports,
aiming to describe the verbatim terms used. However,
decisions needed to be made during the process re-
garding criteria that could be conflated (e.g. spondylo-
listhesis grade I and spondylolisthesis grade II) to
achieve useful data reduction and facilitate interpret-
ation of results. These decisions were made through
team discussion and the framework was revised and
refined until all the coded data could be modelled
within the structure of the framework.
We populated each theme and subtheme of our frame-
work with frequencies of reporting. Frequency distribu-
tions were used to summarise the prevalence of reported
criterion. All quantitative descriptive analyses were per-
formed using SPSS (IBM, Washington).
Results
Our initial search identified 6001 studies; we examined
full-texts of 311 of these. At full-text level, 143 articles
were excluded [50–192], and 168 met the inclusion cri-
teria [193–360] (Fig. 1) [see Additional file 2]. [see
Additional file 3: Table S1] shows the characteristics of
included studies, and [see Additional file 4: Table S2]
shows the characteristics of excluded studies.
Framework of inclusion and exclusion criteria
Table 2 shows our framework of themes (n = 3) and sub-
themes (n = 27) identified from inclusion criteria, while
Table 3 shows the identified themes (n = 21) and sub-
themes (n = 117) from exclusion criteria.
Inclusion criteria
Demographics
While most studies reported the age, gender and symp-
tom duration of their study population, these demo-
graphics were variably included as inclusion criteria. Age
was reported as selection criterion in 77% of the trials.
The lower age entry threshold was specified in 74% of
trials and spanned from 15 to 45 years. In contrast, an
Fig. 1 Flowchart
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Table 2 Inclusion themes and subthemes
Theme Subthemes n (%)
1 Anatomical area Between costal margins and gluteal folds 8 (5)
Below scapulae and above gluteal folds 3 (2)
T6 or below 2 (1)
T7 or below 2 (1)
Low back or buttocks 2 (1)
Between L1 and gluteal folds 2 (1)
Between L1 and SI-joints 1 (1)
At or above waist level 1 (1)
2 Symptoms and signs Low back pain 150 (89)
With or without referred Leg pain 27 (16)
Back pain 10 (6)
Without referred leg pain 7 (4)
Pain exacerbated by movement 5 (3)
Limited movement 3 (2)
Stiffness 2 (1)
Tension 2 (1)
With referred leg pain 1 (1)
Pain at rest 1 (1)
Discomfort 1 (1)
3 Patient-reported outcome measures
with score thresholds for inclusion
Visual Analogue Scale* (0 to 100)
≥ 40 mm 6 (4)
≥ 30 mm 4 (2)
≥ 65 mm 1 (1)
≥ 35 mm 1 (1)
≥ 20 mm 1 (1)
≥ 10 mm 1 (1)
Oswestry Functional Disability Index (0 to 100%)
≥ 30% 2 (1)
≥ 25% 2 (1)
≥ 20% 1 (1)
≥ 15% 1 (1)
Roland Morris Disability Questionnaire (0 to 24)
≥ 3 points 2 (1)
≤ 4 points 1 (1)
≤ 5 points 1 (1)
Numeric Rating Scale (0 to 10)
≥ 3 points 1 (1)
≥ 2 points 1 (1)
Von Korff Chronic Pain Grade (0 to 4)
≥ Grade 1 1 (1)
Hanover Ability Questionnaire (0 to 100%)
≤ 70% 1 (1)
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upper age entry threshold was specified in 64% of trials
and spanned from 28 to 80 years. Gender was reported
as an inclusion criterion in 13 (8%) trials, either as males
(n = 3), females (n = 2) or both (n = 8).
While most trial reports (n = 124, 74%) defined dur-
ation of back pain as an inclusion criterion, this ranged
from one day to 12 months. Figure 2 shows the propor-
tion of trials that used the terms acute (n = 8), subacute
(n = 9) and chronic (n = 54), or did not report any term
(n = 97). The term ‘chronic’ was used without specifying
duration in 8 trials (5%), while pain of at least 3 months
(n = 27, 16%) was the most commonly specified duration
followed by pain of at least 6 months (n = 9, 5%).
Anatomical area (Table 2, theme one)
Most trial reports (n = 143, 85%) did not designate a
specific anatomical area as an inclusion criterion. For
the 21 (12%) that did, the most common specification
was ‘between the costal margin and above gluteal folds’
(n = 8, 5%), followed by ‘below scapulae and above glu-
teal folds’ (n = 3, 2%).
Symptoms and signs (Table 2, theme two)
While some trial reports were specific when describing
pain symptoms (e.g. ‘pain at rest’) used as inclusion cri-
teria, others defined these more generally (e.g. ‘back
pain’). Most of the reports described symptoms for in-
clusion criteria as ‘low back pain’ (n = 150, 90%),
whereas some used ‘back pain’ even though low back
pain was mentioned elsewhere in the paper (n = 10, 6%).
Further descriptors, such as ‘with or without leg pain’
(n = 27, 16%), and ‘pain exacerbated by movement’ (n =
5, 3%), were used. Forty-three reports (26%) described
more than one symptom, whilst three (2%) used three or
more symptoms as inclusion criteria.
Exclusion criteria
Conditions (Table 3, themes one to 12)
Themes one to 12 (i.e. disorders and/or pathologies used
as exclusion criteria) and their associated sub-themes
could be collectively described as ‘conditions’. Specific
conditions were the most commonly described exclusion
criteria. Most trials (n = 145, 86%) reported at least one
condition as an exclusion criterion. The most frequently
reported back-related conditions were ‘spondylolisthesis’
(n = 35, 21%) and ‘spinal stenosis’ (n = 31, 18%).
Specified, unspecified or implied systemic or rheuma-
tologic or immunologic conditions were most commonly
referred to using terms such as ‘inflammatory disease’
(n = 37, 22%), ‘osteoporosis’ (n = 27, 16%), and ‘rheuma-
tologic disease’ (n = 13, 8%). LBP due to trauma was de-
scribed as a condition for exclusion in 63 (37%) trials,
most commonly fracture, dislocation and trauma, and
major trauma. Psychosocial conditions were exclusion
criteria in 58 (34%) trials, mostly described in umbrella
terms, such as ‘psychiatric disorder’ (n = 35, 20%). Of the
excluded conditions related to malignancy, most trials
described ‘cancer’, while some reported ‘previous cancer’.
Only one trial included ‘significant unexpected weight
loss’, as an exclusion criterion.
Symptoms, signs and other exclusion criteria (Table 3,
themes 13 to 19)
NsLBP was primarily distinguished by exclusion criteria
stating that the back pain was not attributable to a ‘specific
cause’ (n = 22, 13%), or known ‘pathology or disease’ (n =
22, 13%), often being described vaguely. The latter were
mostly termed in umbrella or over-arching terms, for ex-
ample ‘red flags indicating serious spinal pathology’ (n =
21, 12%) or ‘known or suspected serious pathology’ (n =
10, 6%). Several reports (n = 44, 26%) listed examples of
‘pathology or disease’ and ‘specific cause’ and while most
of these indicated the same conditions, the terms used
varied (e.g. tumours, neoplasm and malignancy).
Symptoms and signs included as exclusion criteria
were mostly neurological or inferred neurological condi-
tions. The most prevalent exclusion criteria were ‘nerve
root compromise’ (n = 44, 26%), ‘neurological signs’ (n =
34, 20%) and ‘disc herniation’ (n = 30, 17%). The same
neurological condition was variably described as ‘radicu-
lar pain’, ‘radicular symptoms’, ‘radiculopathy’ and ‘sciat-
ica’. Some trial reports (n = 32, 19%) described
assessment methods to exclude people with neuro-
logical signs and symptoms. These were based on
radiographic evidence (n = 16, 9%) and clinical exam-
ination (n = 16, 9%); for example, ‘positive Straight Leg
Raising, and diminished or decreased motor, sensory,
and reflex function’.
Table 2 Inclusion themes and subthemes (Continued)
Theme Subthemes n (%)
Short-From 36
“moderate pain and moderate disability
(measured by adaptations of items 7 and 8 of SF-36)”
1 (1)
Brief Pain Inventory (0 to 10 on Average pain)
“4 points on average pain last 6 months” 1 (1)
*Visual Analogue Scale transformed to 0 to 100 mm
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Table 3 Exclusion themes and subthemes
Themes Subthemes n (%)
1 Back-related condition Spondylolisthesis 35 (21)
Spinal stenosis 31 (18)
Spondylolysis 13 (8)
Ankylosing spondylitisa 8 (5)
Structural deformity 7 (4)
Osteoporotic fracture 6 (4)
Congenital deformation 6 (4)
Disc disease 3 (2)
Sacroiliitis 3 (2)
Severe structural deformity 3 (2)
Scoliosis 2 (1)
Active structural deficit 2 (1)
Severe postural abnormality 2 (1)
2 Specified, unspecified, implied systemic,
rheumatologic or immunologic conditions
Inflammatory disease 37 (22)
Osteoporosis 27 (16)
Rheumatological disease 13 (8)
Rheumatoid arthritis 12 (7)
Fibromyalgia 9 (5)
Autoimmune disease 4 (2)
Reactive arthritisb 2 (1)
Bone disease 2 (1)
Osteoarthritis 2 (1)
Inflammatory arthritis 1 (1)
Arthritis 1 (1)
Systemic Lupus Erythematosus 1 (1)
Myofascial pain syndrome 1 (1)
Articular impairment 1 (1)
3 Psychological Psychiatric disorders 35 (21)
Depression 11 (6)
Severe psychiatric disorder 8 (5)
Impaired cognition 7 (4)
4 Other systemic, unspecified Systemic disease 15 (9)
Metabolic disease 10 (6)
Visceral disease 9 (5)
Endocrine disorder 2 (1)
Uterine disease 1 (1)
Thyroid dysfunction 1 (1)
5 Trauma 63 (37)
6 Malignancy 78 (46)
7 Infectious Infection 42 (25)
Infectious spondylopathy 5 (3)
Infectious disease 4 (2)
Previous infection 1 (1)
Abscess 1 (1)
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Table 3 Exclusion themes and subthemes (Continued)
Themes Subthemes n (%)
8 Cardiovascular Cardiac disease /insufficiency 32 (19)
Vascular disease /insufficiency 13 (8)
Hypertension 6 (4)
Ischemic heart attack 2 (1)
Claudication 2 (1)
Aortic aneurysm 1 (1)
9 Haematological Bleeding disorders 5 (3)
Blood coagulation disorder 2 (1)
10 Respiratory Respiratory disease /insufficiency 14 (8)
11 Gastrointestinal, liver or renal Severe renal or hepatic disorder 5 (3)
Liver disease 2 (1)
Gastrointestinal disease 2 (1)
Abdominal hernia 2 (1)
Gastritis 1 (1)
Gastric ulcer 1 (1)
Crohn’s disease 1 (1)
Inguinal hernia 1 (1)
12 Neurological, systemic Myelopathy 2 (1)
Epilepsy 2 (1)
Seizure disorders 1 (1)
Muscular disease 1 (1)
Muscular dystrophy 1 (1)
13 General indications of spinal pathology Pathology or disease “such as” / “e.g” 22 (13)
Specific cause “such as” / “e.g” 22 (13)
Red flags indicating serious spinal pathology 21 (12)
Specific cause identified 14 (8)
Known or suspected serious pathology 10 (6)
Non-mechanical low back pain 1 (1)
14 Neurological related to the back (symptoms or
signs or specific conditions referable to involvement
of the spinal cord or nerve roots)
Nerve root compromise 44 (26)
Neurological signs 34 (20)
Disc herniation 30 (18)
Sciatica 17 (10)
Radicular symptoms 16 (9)
Signs of nerve root irritation 15 (9)
Cauda equina syndrome 14 (8)
Radiation below knee 13 (8)
Radiculopathy 10 (6)
Progressive neurological signs 4 (2)
Radicular pain 4 (2)
Widespread neurological signs 3 (2)
Leg symptoms 3 (2)
Spondylolisthesis with radiculopathy 1 (1)
Cord compression 1 (1)
Paralysis 1 (1)
15 Previous or scheduled surgery 84 (50)
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Table 3 Exclusion themes and subthemes (Continued)
Themes Subthemes n (%)
16 Pregnancy-related Pregnancy 81 (48)
Pre-eclampsia 1 (1)
17 Medico-legal issues 39 (23)
18 Comorbidities Comorbidities 2 (1)
Urine or faecal incontinence 1 (1)
19 Exclusion for feasibility Not understanding language 28 (17)
Other current treatment 18 (11)
Previous specific treatment 17 (10)
Medication 13 (8)
Contraindications for intervention 8 (5)
Cardiac pacemaker 6 (4)
Current alcohol abuse 3 (2)
Unable to commit to home-exercises 3 (2)
Fever on the day of examination 3 (2)
History of psychosis 2 (1)
History of alcohol abuse 2 (1)
Presence of yellow flags 1 (1)
20 Miscellaneous Obesity
Body Mass Index ≥30 4 (2)
Body Mass Index ≥40 3 (2)
Obesity (not specified) 2 (1)
Body Mass Index ≥35 1 (1)
Body Mass Index ≥28 1 (1)
Menstruation 1 (1)
Unable to sit on a stationary bike 1 (1)
Bad balance between trunk flexors and extensors 1 (1)
Inability to walk at least 100 m without interruption 1 (1)
Neurologic impairment 1 (1)
Behaviour precluding participation in group therapy 1 (1)
Evidence of distress 1 (1)
Patients unable to accurately locate the area of pain 1 (1)
Patient unable to walk without a walking aid 1 (1)
Suspected non-compliance 1 (1)
21 Patient-reported outcome measures
with score thresholds for exclusion
Visual Analogue Scale (0 to 100)c
≥ 60 mm 2 (1)
≥ 80 mm 2 (1)
Beck Depression Inventory (0 to 63)
≥ 20 points 1 (1)
≥ 29 points 1 (1)
Bothersomeness scale (0 to 10)
≤ 3 points 1 (1)
Numeric Rating Scale (0 to 10)
≥ 80 points 1 (1)
aBechterew is an eponymous term for ankylosing spondylitis, and was reported in two trials; bTwo trials used a banned eponymous term to refer to
reactive arthritis. cVisual Analogue Scale transformed to mm
Amundsen et al. BMC Musculoskeletal Disorders  (2018) 19:113 Page 8 of 13
Some specific exclusion criteria related to safeguarding
the integrity and/or feasibility of the trial. These in-
cluded exclusion of potential participants who were
scheduled for surgery or who had previous surgery re-
lated to the back (n = 84, 50%), pregnancy (n = 81, 48%),
medicolegal issues (n = 39, 23%), ‘not understanding the
language’ (n = 28, 16%), ‘other current treatment’ (n = 18,
11%) or participant’s prior experience with a given treat-
ment (n = 17, 10%).
‘Miscellaneous’ exclusion criteria (Table 3, theme 20)
A ‘miscellaneous’ theme included exclusion criteria that
were vague, insofar as the meaning or relevance to
nsLBP was unclear, rarely reported, or were less easy to
categorise. Obesity was reported as an exclusion criter-
ion in 10 trials (6%) with a Body Mass Index of 30 or
more (n = 4, 3%), or 40 or more (n = 3, 2%) most fre-
quently reported.
Examples of further miscellaneous subthemes include:
‘articular impairment’, ‘menstruation’, ‘being unable to sit
on a stationary bike’, ‘bad balance between trunk flexors
and extensors’, ‘neurologic impairment’, and individuals
with ‘evidence of distress’.
Patient-reported outcome measure score thresholds
(inclusion theme 3 and exclusion theme 21)
Thirty-three trials (20%) included a patient-reported out-
come measure score threshold as a selection criterion.
The Visual Analogue Scale (VAS) for pain intensity was
most utilised as both an inclusion (n = 14, 8%) and ex-
clusion criterion (n = 4, 2%); the range of VAS score for
inclusion was 10 to 65 mm (mean 34 mm) (Table 2),
whereas the range of VAS score for exclusion was 60 to
80 mm (mean 70 mm) (Table 3).
Discussion
Results of this study show that the reported eligibility
criteria of people with nsLBP across RCTs is diverse.
Trial reports provided relatively fewer details for inclu-
sion criteria than they did for exclusion criteria.
Explicitly reported selection criteria were diverse and
only 46% explicitly reported the exclusion of malignancy.
However, exclusion of malignancy in the remaining trials
may have been assumed to be implied by the definition
of nsLBP. Fewer than half of the trials reported neuro-
logical compromise as exclusion criteria, whereas only
one quarter of trials reported the inclusion of people
‘with or without referred pain’. While most trials re-
ported specific pathologies as exclusion criteria, many of
the terms used to describe these were ambiguous or
vague, making it difficult to ascertain how these were
operationalised. Psychological conditions were reported
as exclusion criteria in one-third of trials, which is a sur-
prising finding when the literature proposes that psycho-
logical disorders may be a predictor of chronicity in LBP
as well as comorbid with pain [31–33]. Use of umbrella
or over-arching terms, without specific descriptions of
what these were, was frequently seen across all categor-
ies of symptoms, signs, and conditions. For example,
identification of ‘red flags’ was used as an exclusion cri-
terion in several trials, despite the vagueness of the term
(i.e. ‘red flags’ can mean different things) and the weak
supporting evidence for red flags determining the pres-
ence of a specific cause [34].
Our findings demonstrate the heterogeneity of the se-
lection criteria of RCTs purporting to be studying similar
populations. The application of these criteria is typically
poorly described, creating difficulty for making judge-
ments on the comparability of study populations.
Fig. 2 Pie chart of terms used for duration
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Explicit reporting of clearly defined inclusion and exclu-
sion criteria, using consistent terminology, would in-
crease our confidence in the clinical homogeneity of
nsLBP trial populations, increase the validity of meta-
analyses, and improve our ability to interpret and com-
pare the results of individual RCTs and systematic
reviews.
RCTs that include or exclude people without clear
diagnostic criteria or procedure, could lead to includ-
ing individuals with different prognoses. Without
clear, unambiguous descriptions, the utility of report-
ing exclusion criteria is limited. For example, interver-
tebral disc herniation is evident in many
asymptomatic individuals, and it may often be the
case that participants with asymptomatic herniations
are admitted into a trial [35, 36].
Of the subthemes of selection criteria that we
judged as particularly relevant to back pain, there was
inconsistent application between RCTs. For example,
spondylolisthesis and spinal stenosis were reported as
exclusion criteria in only 20% of trials, but may have
been included under the often-reported general indi-
cations of spinal pathology such as ‘known or sus-
pected pathology’ or ‘specific cause identified’.
Psychosocial conditions were often reported; however,
yellow flags were only reported within the selection
criteria of one trial [37].
Selection criteria depend on the intervention being
tested; there may be good reason for disproportionate
focus on biological, psychological or sociological fac-
tors. Notwithstanding, over recent decades psycho-
social aspects of low back pain have gained much
attention [38]. Studies have highlighted the import-
ance of psychosocial factors in the transition from
acute to chronic pain; however, we note that few tri-
als used questionnaires designed to assess psycho-
logical aspects of pain in relation to the selection of
suitable participants for nsLBP trials [38–41].
Comparisons with existing research
Research on criteria for participating in trials has investigated
case definitions and duration of LBP, and specific inclusion
and exclusion criteria (e.g. age, though not specifically for
nsLBP). These studies show ambiguous presentation of case
definitions, duration, and a variation in reported criteria and
diagnostic criteria specifically for exclusion of neurological
conditions [18, 25, 42]. These results are consistent with our
findings. Similar ambiguities have also been described by sys-
tematic reviews of trials of interventions for treatment of
conditions of the shoulder [43, 44] and neck [45].
Our study empirically corroborates the consensus view of
the NIH consortium that clinical studies use variable inclu-
sion/exclusion criteria, and supports the NIH Task Force’s
call to develop and draft research standards for chronic low
back pain (cLBP) [24]. We hope that this work will be useful
in starting and informing discussion surrounding consensus
on appropriate entry criteria and what constitutes sufficient
detail to adequately describe cLBP study populations.
Strengths and limitations
This review utilised a systematic multi-reviewer approach
and methods developed a priori to review and categorise
the selection criteria in nsLBP RCTs. The review has sev-
eral limitations, which must be acknowledged. The trials
investigated were published between 2006 and 2012; thus,
more recently published reports are not represented. Prior
to 2006 there were changes in the quality of trial reporting
following the introduction of CONSORT [46]. Our view is
that there is no reason to expect that any large recent
change in entry criteria would materially change our find-
ings. The Task Force Report on Research Standards for
Chronic Low-Back Pain was published in 2014 and
emphasised the variation in inclusion and exclusion cri-
teria, which may have influenced nsLBP trial investigators
to become increasingly aware of describing criteria more
homogenously [24].
To identify the selection criteria of included trials, we
only searched the methods sections. Therefore, it is pos-
sible that additional information about selection criteria
could have been reported elsewhere in the paper. We
also only included English language papers and it is pos-
sible (although unlikely) that our findings may not be
generalisable to non-English-language reports. We used
an iterative method to describe the selection criteria of
included trials and merged some categories together for
ease of presentation. While other more complex categor-
isations could have been used, we don’t think is likely to
have altered the key findings.
Recommendations for future nsLBP trials and future
research
Following our experience of the challenges of categoris-
ing and making a taxonomy of entry criteria domains,
we provide in Table 4, for commonly reported domains,
examples of the level of detail we suggest is required for
the parameters of entry criteria to be sufficiently clear.
We offer these suggestions in the spirit of starting and
informing discussion surrounding the development of
consensus on both clinically relevant domains of entry
criteria for LBP trials, and the level of detail required for
clarity in the description of how the criterion was opera-
tionalised. This approach has worked well previously,
where consensus processes have begun with some initial
suggestions that are then assessed, scrutinised, and then
refined [47, 48]. We confined ourselves here to making
suggestions for only commonly reported domains; al-
though empirical research on what has happened in the
past may or may not be the most desirable for informing
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consensus on what should be done in the future. While
consistency with what has gone before has value insofar
as it facilitates between-trial comparisons, the questions
surrounding domain choice and the level of detail that
should be provided are principally clinical and in our
view, would benefit from separate independent consider-
ation within a Delphi process. [49].
Our paper provides a useful basis for making compari-
sons with evaluations of nsLBP trials published after
2012 and after the 2014 publication of the NIH report
[24]. It will also be important to determine whether
there is any improvement in the reporting of selection
criteria in future nsLBP trials based upon this paper and
our suggested template.
Conclusion
Inclusion and exclusion criteria in RCTs of nsLBP are di-
verse, and terms and descriptions used are inconsistent
and often described ambiguously using over-arching
terms. The use of more consistent selection criteria and
unambiguous reporting of these should improve popula-
tion homogeneity between trials, facilitating compari-
sons and meta-analyses. We offer a template of criteria
as a starting point that may be adapted, if required, de-
pending on the intervention under investigation.
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Table 4 Suggested examples for the clear reporting of entry criteria, by commonly reported domains
Criterion/a Examples
Anatomical region Pain between bottom of ribs and buttock creases
If pain below buttock creases is excluded; state any explicit criteria
for exclusions
Pain radiating below knee or objective neurological signs in leg
Age Adults – with restrictions by age only if good scientific/clinical reason
Duration Back pain problem that has persisted at least 3 months and has resulted
in pain on at least half the days in the past 6 months
Serious causes of LBP excluded Malignancy, vertebral fracture, infections
Rheumatologic conditions excluded Ankylosing spondylitis or related conditions
Systemic conditions excluded Cardiovascular, respiratory, neurological, gastrointestinal, urogenital or
related conditions
Baseline severity for studies of treatment (i.e not prevention) NRS/VAS≥ 4/40, or≥ 15% of score range of a disability measure
(e.g 4/24 for RMDQ)
Other patient-characteristics excluded Pregnancy, medico-legal issues, not understanding language, previous or
scheduled surgery, psychiatric disorders
Study specific criteria Workers or men or with/without depression
Note: The table shows, for commonly reported domains, a series of examples of the level of detail we suggest is required for the parameters of entry criteria to be
sufficiently clear
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